Molecular Formula | C11H22ClN |
Molar Mass | 203.75 |
Melting Point | >240°C (dec.) |
Solubility | ethanol: 122mg/mL |
Appearance | neat |
pKa | pKa 11.2(H2O,t undefined,I=0.1) (Uncertain) |
Storage Condition | 2-8°C |
In vitro study | Mecamylamine blocks muscle nAChRs in a use- and voltagedependent manner. Mecamylamine blocks the nicotinic currents via trapping mechanism. The main feature of this block is the phenomenon of block relief, which might be revealed by combined action of depolarization and activation of nAChRs. The experimental study of the Mecamylamine action on muscle nAChRs revealed that: (1) Mecamylamine (1-20 μM) reduces evoked end-plate currents (EPC) amplitude with Hill’s constant equal to 1.2 and IC 50 = 7.8 μM at holding potential –70 mV; (2) the calculated depth of its interaction with the muscle nAChR channel is almost half of the one of neuronal nAChRs (0.37 compare to 0.72 for neuronal nAChRs); (3) simultaneous membrane depolarization and repetitive activation of postsynaptic nAChRs by motor nerve stimulation produced rapid block relief dependent on the degree of depolarization, number of conditioning signals and Mecamylamine concentration, and only slightly depended on the rate of stimulation. |
Hazard Symbols | Xn - Harmful |
Risk Codes | R22 - Harmful if swallowed R36/37/38 - Irritating to eyes, respiratory system and skin. |
Safety Description | 36/37/39 - Wear suitable protective clothing, gloves and eye/face protection. |
UN IDs | UN 2811 6.1/PG 3 |
WGK Germany | 3 |
RTECS | RB6900000 |
HS Code | 2921300000 |
Hazard Class | 6.1 |
EPA chemical substance information | information provided by: ofmpeb.epa.gov (external link) |
biological activity | mecanylamine hydrochloride is an orally active, non-selective, non-competitive nAChR antagonist, has anti-nerve disease effect. Mecanylamine hydrochloride is a ganglionic blocker with potential for use in Hypertension Research. Mecamylamine hydrochloride can easily cross the blood-brain barrier. |
Target | nAChR |
Animal Model: | C57BL/6J mice (3-4 months) forced swim test (FST) and tail suspension test (TST) |
Dosage: | 0.5 mg/kg, 0.75 mg/kg, 1 mg/kg |
Administration: | Intraperitoneal injection |
Result: | Significantly decreased immobility time in the TST at the 1.0-mg/kg dose but did not alter baseline locomotor activity. Also significantly decreased time immobile in the FST. |